Jove
Visualize
お問い合わせ

関連する概念動画

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
T Cell Types and Functions01:24

T Cell Types and Functions

2.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.0K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

14.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.5K
Lineage Commitment01:21

Lineage Commitment

4.0K
Commitment is the  process whereby stem cells:
4.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  1. ホーム
  3. 腫瘍の微小環境の違い Tヘルパー系統の指示 免疫チェックポイント療法への反応
  1. ホーム
  3. 腫瘍の微小環境の違い Tヘルパー系統の指示 免疫チェックポイント療法への反応

関連する実験動画

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K

腫瘍の微小環境の違い Tヘルパー系統の指示 免疫チェックポイント療法への反応

Shiping Jiao1, Sumit K Subudhi2, Ana Aparicio2

  • 1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center UTHealth, Houston, TX 77030, USA.

Cell
|November 16, 2019

PubMed で要約を見る

まとめ
この要約は機械生成です。

免疫チェックポイント療法 (ICT) は,骨転移した前立腺がんでは効果が低い. TGF-βを阻害すると,Th1応答が強化され,骨転移性除抵抗性前立腺がん (mCRPC) モデルにおける生存率が改善されます.

キーワード:
T (h) 1 サブセットTGF-βブロックアンチCTLA-4アンチPD-1骨転移カストレーションに抵抗する前立腺がん

さらに関連する動画

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

8.0K
Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

31.0K

関連する実験動画

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

8.0K
Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

31.0K

科学分野:

  • 腫瘍学
  • 免疫学
  • 癌 研究

背景:

  • 免疫チェックポイント療法 (ICT) は,転移性カストレーション抵抗性前立腺がん (mCRPC) に対して有望である.
  • しかし,骨転移の患者ではICTの有効性は限られている.
  • 骨髄分析は,ICT後にTh1細胞よりもTh17細胞へのシフトを明らかにしています.

研究 の 目的:

  • mCRPCにおけるICT対応に対する腫瘍微環境の影響を調査する.
  • 骨転移におけるICTの有効性を阻害するメカニズムを解明する.
  • 骨のmCRPCにおけるICT成果の改善のための戦略を特定する.

主な方法:

  • ネズミの皮膚下および骨内前立腺腫瘍モデルの比較
  • 腫瘍内T細胞サブセット (Th1,Th17,CD8) の分析
  • オステオクラスト媒介による骨再吸収とTGF-βシグナル伝達の調査
  • 結合ICTとTGF-β阻害療法の評価

主要な成果:

  • ICTは,Th1細胞を増やすことで,皮下モデルでの生存率を向上させました.
  • ICTは,Th17の極化で,骨モデルで抗腫瘍反応を誘発することができなかった.
  • 腫瘍誘発の骨格細胞活性がTGF-βを放出し,骨のTh1発育を抑制する.
  • ICTと共にTGF-βを阻害すると,Th1とCD8のT細胞の拡張が促進され,腫瘍の収縮と生存率が向上しました.

    • 結論:

    • 骨腫瘍の微環境はTh17の分極化を促進し,TGF-βによるICTの有効性を阻害する.
    • TGF-βをICTと併用して標的化することは,骨のmCRPCに対する有望な治療戦略です.
    • このアプローチは,抗腫瘍T細胞の反応を強化し,臨床前モデルでの生存率を改善します.